List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 933 studies with search of:   "Doxorubicin"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Not yet recruiting A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Conditions: Cancer;   Carcinoma;   Fallopian Tube Cancer;   Gynecological Malignancies;   Metastases;   Oncology;   Ovarian Cancer;   Solid Tumors;   Tumors
Interventions: Drug: Part 2, Cohort A: AMG 386 MTD Part 1 + Liposomal doxorubicin;   Drug: B1: AMG 386 10 mg/kg + Topotecan;   Drug: B2: AMG 386 3mg/kg + Topotecan;   Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin;   Drug: A2: AMG 386 3mg/kg + Liposomal doxorubicin;   Drug: Part 2, Cohort B: AMG 386 MTD part 1 + Topotecan
2 Recruiting A Scandinavian Sarcoma Group Protocol for Patients With High-Risk Soft Tissue Sarcoma of the Extremities and Trunk Wall
Conditions: Soft Tissue Sarcoma;   Non Metastatic Disease
Interventions: Drug: doxorubicin , ifosfamide;   Drug: doxorubicin, ifosfamide;   Drug: doxorubicin, ifosfamide;   Drug: doxorubicin, ifosfamide
3 Recruiting A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Interventions: Drug: Palifosfamide Tris and Doxorubicin;   Drug: Doxorubicin
4 Completed Vincristine, DOXIL® (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Conditions: Myeloma Proteins;   Multiple Myeloma;   Myeloma;   M-Protein
Intervention: Drug: Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)
5 Completed Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
Condition: Primary Breast Cancer
Interventions: Drug: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen;   Drug: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid
6 Recruiting A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Liposomal Doxorubicin/Melphalan/Bortezomib
7 Recruiting Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer
Condition: Early-Stage Breast Cancer
Interventions: Drug: genomically-guided treatment: Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC);   Drug: non-genomically-guided treatment: Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)
8 Recruiting Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)
Condition: Prostate Cancer
Interventions: Drug: Thalidomide;   Drug: Doxil® (doxorubicin HCL liposome injection)
9 Recruiting Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Taxotere;   Drug: Adriamycin/Cytoxan;   Drug: docetaxol;   Drug: doxorubicin
10 Recruiting Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Pegylated liposomal doxorubicin (Caelyx);   Drug: Epirubicin
11 Active, not recruiting A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma
Conditions: Sarcoma, Kaposi;   HIV Infections
Interventions: Drug: Doxorubicin hydrochloride (liposomal);   Drug: Bleomycin sulfate;   Drug: Vincristine sulfate;   Drug: Doxorubicin hydrochloride
12 Active, not recruiting BIG 02/98 Docetaxel - Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Doxorubicine + docetaxel sequential;   Drug: doxorubicine + cyclophosphamide sequential;   Drug: doxorubicine + cyclophosphamide combined;   Drug: doxorubicine + docetaxel combined
13 Recruiting Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone;   Drug: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
14 Recruiting Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
Conditions: Solid Tumor;   Urethral Cancer
Interventions: Drug: Bortezomib;   Drug: Gemcitabine;   Drug: Doxorubicin
15 Recruiting Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Carcinoma;   Epithelial Ovarian Carcinoma
Intervention: Drug: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
16 Completed German Preoperative Adriamycin Docetaxel Study
Condition: Breast Neoplasms
Interventions: Drug: doxorubicin, docetaxel, tamoxifen;   Drug: doxorubicin, docetaxel
17 Recruiting Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: liposomal Doxorubicin;   Drug: Vincristin;   Drug: Prednisolone
18 Active, not recruiting Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
Conditions: High Risk;   Breast Cancer;   Positive Nodes;   Cyclophosphamide;   Doxorubicin
Interventions: Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: G-CSF;   Drug: tamoxifen;   Drug: ciprofloxacin
19 Recruiting Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed MM
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide, Pegylated Liposomal Doxorubicin, Dexamethasone
20 Not yet recruiting Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: MYOCET® Plus Cyclophosphamide and Trastuzumab, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles;   Drug: Free Doxorubicin Plus Cyclophosphamide, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles

Previous Page Studies Shown (1-20) Next (21-40)
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services